Skip to main content

Table 3 Comparison between GS 6 disease and more aggressive disease in PCa patients

From: Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study

  GS 6 GS ≥ 7 P value
  N, 15 (23.8%) N, 48 (76.2%)
Age, yr 73.0 (9.0) 72.0 (12.0) 0.520
tPSA, ng/mL 7.47 (4.6) 9.75 (23.6) 0.156
fPSA 0.97 (0.6) 1.13 (1.7) 0.358
%fPSA 13.08 (8.0) 10.98 (9.2) 0.302
p2PSA, pg/mL 13.9 (13.4) 45.3 (72.6) 0.001
%p2PSA 1.26 (1.0) 3.17 (2.2) < 0.001
PHI 35.4 (28.0) 120.8 (148.6) < 0.001
Positive core number 3.0 (4.0) 6.0 (6.0) 0.032
  1. Data are shown as median (interquartile range), or number (%)
  2. PSA , prostate-specific antigen; tPSA, total PSA; fPSA = free PSA; p2PSA, [2]proPSA; PHI, prostate health index; GS, Gleason score
  3. P value to be statiscally significant with bolditalics